Xeris Biopharma Holdings, Inc. (2B30)
XMUN 
Summary
2B30 Chart
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right
Xeris Biopharma has delivered another year of significant revenue growth, signaling a pivotal moment in its trajectory. XERS has reached an inflection point, indicating a shift in its business momentum and future prospects. The article highlights the company's expanding injectable medication portfolio as a driver for recent and anticipated growth.
Xeris Biopharma Q1 Earnings Call Highlights
Xeris Biopharma NASDAQ: XERS reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution across its commercial portfolio.
Xeris Biopharma Holdings, Inc. (2B30) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Xeris Biopharma Holdings, Inc. ever had a stock split?
Xeris Biopharma Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | John Shannon CEO | XMUN Exchange | US98422E1038 ISIN |
| US Country | 435 Employees | - Last Dividend | - Last Split | 21 Jun 2018 IPO Date |
Overview
Xeris Biopharma Holdings, Inc. is an innovative biopharmaceutical company based in Chicago, Illinois, with a strong commitment to enhancing patient care by developing and commercializing unique therapies. Founded in 2005, Xeris Biopharma has embarked on a mission to address unmet medical needs through its diverse portfolio of products. The company particularly focuses on leveraging its proprietary non-aqueous XeriSol and XeriJect formulations technologies to create and deliver better pharmacological solutions. These technologies are designed to enable stable, ready-to-use, injectable and infusible drug formulations that can improve patient compliance, convenience, and efficacy across a wide range of therapeutic areas. Xeris Biopharma’s forward-looking approach emphasizes the development of treatments that cater to pediatric and adult patients alike, with its products receiving approval for significant medical conditions such as severe hypoglycemia, primary periodic paralysis, Cushing's syndrome, and hypothyroidism.
Products and Services
- Gvoke
- Keveyis
- Recorlev
- XP-8121
- XeriSol and XeriJect Technologies
A revolutionary ready-to-use, liquid stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients. Gvoke represents a significant advancement in the emergency management of diabetic patients who experience severe hypoglycemia, offering ease of use and rapid effectiveness.
Keveyis addresses the needs of patients suffering from hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. As the first and only FDA-approved treatment for these conditions, Keveyis significantly improves the quality of life for individuals affected by these rare disorders.
This cortisol synthesis inhibitor is specifically aimed at treating adult patients with Cushing's syndrome, a condition characterized by excessive levels of the hormone cortisol. Recorlev has been proven to reduce cortisol levels, mitigating the symptoms and complications associated with this disorder.
Currently under development, XP-8121 is a promising once-weekly subcutaneous injection of levothyroxine intended for the treatment of hypothyroidism. Being in phase I clinical trial, XP-8121 aims to improve the standard of care by offering a more convenient dosing regimen compared to daily oral levothyroxine therapies.
Xeris Biopharma's proprietary non-aqueous formulation technologies, XeriSol and XeriJect, enable the development of stable, ready-to-use, injectable and infusible drug formulations. These platforms are instrumental in creating improved versions of existing therapies, potentially enhancing patient compliance, convenience, and efficacy.
